位置:首页 > 产品库 > MK-5172 sodium salt
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MK-5172 sodium salt
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
MK-5172 sodium salt图片
CAS NO:1425038-27-2
包装与价格:
包装价格(元)
5mg询价
10mg询价
50mg询价
100mg询价

MK-5172 sodium salt (MK-5172 sodium salt) 是丙型肝炎病毒 NS3/4a 蛋白酶的选择性抑制剂,对基因型和耐药变异具有广泛的活性,Kis 为 0.01 nM (gt1b)、0.01 nM (gt1a)、0.08 nM (gt2a)、0.15 nM (gt2b)、0.90 nM (gt3a)。
Cas No.1425038-27-2
别名MK5172 sodium salt;MK 5172 sodium salt
Canonical SMILESCC(C)(C1C(N2CC(OC3=NC4=C(N=C3CCCCCC5CC5OC(N1)=O)C=CC(OC)=C4)CC2C(NC6(C(NS(=O)(C7CC7)=O)=O)CC6C=C)=O)=O)C.[Na+]
分子式C38H50N6NaO9S+
分子量789.89
溶解度Soluble in DMSO
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述 IC50 Value: 7.4nM and 7nM for genotype1b and 1a respectively, in replicon system [1] MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development. in vitro: In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a [2]. in vivo: In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose [1]. Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C . Phase1
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024